Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma

• Published in: Scientific reports Vol. 10; no. 1; p. 15715
• Main Authors: Takeda, Atsunobu, Hasegawa, Eiichi, Nakao, Shintaro, Ishikawa, Keijiro, Murakami, Yusuke, Hisatomi, Toshio, Arima, Mitsuru, Yawata, Nobuyo, Oda, Yoshinao, Kimura, Kazuhiro, Yoshikawa, Hiroshi, Sonoda, Koh-Hei
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.09.2020
• Subjects: 631/250/127/1213; 631/67/1484; 631/67/327; 692/53/2422; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - metabolism; Female; Humanities and Social Sciences; Humans; Interleukins - metabolism; Lymphoma, B-Cell - metabolism; Lymphoma, B-Cell - mortality; Lymphoma, B-Cell - pathology; Male; Middle Aged; multidisciplinary; Prognosis; Retinal Neoplasms - metabolism; Retinal Neoplasms - mortality; Retinal Neoplasms - pathology; Retrospective Studies; Science; Science (multidisciplinary); Survival Rate; Vitreous Body - metabolism; Vitreous Body - pathology
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-72962-z

Vitreoretinal lymphoma (VRL) is a rare disease of B-cell origin with poor prognosis. Regulatory cytokines promote tumor development by suppressing antitumor immunity in several cancer types, including B-cell malignancies. To identify the regulatory cytokines associated with poor prognosis in patients with B-cell VRL, we determined the regulatory cytokines profiles in the vitreous humor of patients with VRL. This retrospective study included 22 patients with VRL, 24 with non-infectious uveitis (NIU), and 20 with idiopathic epiretinal membrane (control). Vitreous concentrations of regulatory cytokines were assessed using a cytometric beads assay and association with clinical data was examined. IL-35 and soluble IL-2 receptor α levels were significantly higher in patients with VRL and NIU than those in the control group. The 5-year overall survival (OS) rates for the group with high intravitreal IL-35 was significantly poorer than those for the group with low intravitreal IL-35, who were diagnosed with VRL at the onset ( P  = 0.024, log-rank test). The 5-year OS rates with intravitreal IL-35 levels above and below the median were 40.0% and 83.3%, respectively. Our results suggest that high intravitreal IL-35 levels indicate poor prognosis for patients diagnosed with B-cell VRL at the onset.